This is a repository copy of a meta-analysis of the relation between therapeutic alliance and treatment outcome in eating disorders.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/112081/

Version: Accepted Version

Article:

https://doi.org/10.1002/eat.22672

Reuse
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
A Meta-Analysis of the Relation between Therapeutic Alliance and Treatment Outcome in Eating Disorders

Tiffany A. Graves\textsuperscript{a}, Nassim Tabri\textsuperscript{a}, Heather Thompson-Brenner\textsuperscript{a}, Debra L. Franko\textsuperscript{a}, and Kamryn T. Eddy\textsuperscript{a}

\textsuperscript{a}Massachusetts General Hospital and Harvard Medical School

Stephanie Bourion-Bedes\textsuperscript{b}

\textsuperscript{b}Centre Hospitalier Lorquin

Amy Brown\textsuperscript{c}

\textsuperscript{c}Eating Disorder Service, South London and Maudsley NHS Foundation Trust

Michael J. Constantino\textsuperscript{d}

\textsuperscript{d}University of Massachusetts-Amherst

Christoph Flückiger\textsuperscript{e}

\textsuperscript{e}University of Wisconsin-Madison and University of Bern

Sarah Forsberg\textsuperscript{f}

\textsuperscript{f}Stanford University School of Medicine

Leanna Isserlin\textsuperscript{g}

\textsuperscript{g}University of Ottawa

Jennifer Couturier\textsuperscript{h}

\textsuperscript{h}McMaster Children’s Hospital

Gunilla Paulson Karlsson\textsuperscript{i}

\textsuperscript{i}The Sahlgrenska University Hospital

Johannes Mander\textsuperscript{j}

\textsuperscript{j}University of Heidelberg
Martin Teufel\textsuperscript{k}

\textsuperscript{k}Medical University Hospital

James E. Mitchell\textsuperscript{l}

\textsuperscript{l}University of North Dakota School of Medicine and Health Sciences and the Neuropsychiatric

Ross D. Crosby\textsuperscript{m}

\textsuperscript{m}Neuropsychiatric Research Institute and University of North Dakota School of Medicine and Health Sciences

Claudia Prestano\textsuperscript{n}

\textsuperscript{n}Niccolò Cusano Roma

Dana A. Satir\textsuperscript{o}

\textsuperscript{o}University of Denver

Susan Simpson\textsuperscript{p}

\textsuperscript{p}University of South Australia

Richard Sly\textsuperscript{q}

\textsuperscript{q}University of East Anglia

J. Hubert Lacey\textsuperscript{r}

\textsuperscript{r}St. George's University of London

Colleen Stiles-Shields\textsuperscript{s}

\textsuperscript{s}Northwestern University Feinberg School of Medicine and University of Chicago

Giorgio A. Tasca\textsuperscript{t}

\textsuperscript{t}University of Ottawa and the Ottawa Hospital

Glenn Waller\textsuperscript{u}

\textsuperscript{u}University of Sheffield
Shannon L. Zaitsoff

Simon Fraser University

Renee Rienecke

The University of Michigan Comprehensive Eating Disorders Program

Daniel Le Grange

University of California, San Francisco

Jennifer J. Thomas

Massachusetts General Hospital and Harvard Medical School

Correspondence concerning this article should be addressed to Jennifer J. Thomas, Ph.D., Eating Disorders Clinical and Research Program, Massachusetts General Hospital, 2 Longfellow Place, Suite 200, Boston, MA 02114. Phone: 617-643-6306. Fax: 617-726-1595. Email: jjthomas@mgh.harvard.edu
Abstract

**Objective:** The therapeutic alliance between patient and therapist has demonstrated an association with favorable psychotherapeutic outcomes in the treatment of eating disorders (EDs). However, questions remain about the inter-relationships between early alliance, early symptom improvement, and treatment outcome. We conducted a meta-analysis on the relations among these constructs, and possible moderators of these relations, in psychosocial treatments for EDs. **Method:** Twenty studies met inclusion criteria and supplied sufficient supplementary data. **Results:** Results revealed small-to-moderate effect sizes, $\beta$s = .13 to .22 ($p < .05$), indicating that early symptom improvement was related to subsequent alliance quality and that alliance ratings also were related to subsequent symptom reduction. The relationship between early alliance and treatment outcome was partially accounted for by early symptom improvement. With regard to moderators, early alliance showed weaker associations with outcome in therapies with a strong behavioral component relative to non-behavioral therapies. However, alliance showed stronger relations to outcome for younger (versus older) patients, over and above the variance shared with early symptom improvement. **Discussion:** In sum, early symptom reduction enhances therapeutic alliance and treatment outcome in EDs, but early alliance may require specific attention for younger patients and for those receiving non-behaviorally-oriented treatments.

**Keywords:** eating disorder, meta-analysis, therapeutic alliance, treatment outcome
Therapeutic alliance, defined as the collaborative working relationship between patient and therapist, is one of the most frequently investigated common factors associated with psychotherapy outcome (Horvath, Del Re, Flückiger, & Symonds, 2011; Karver, Handelsman, Fields, & Bickman, 2006; Shirk, Karver, & Brown, 2011). In a meta-analysis of 190 studies of adult patients with various psychiatric diagnoses, alliance correlated moderately with outcome at $r = .28$ (95% confidence interval .25 to .30) (Horvath et al., 2011). A meta-analysis of child and youth psychotherapy had similar findings, $r_w = .22$ (95% confidence interval .16 to .28) (Shirk et al., 2011). Given the robust association between therapeutic alliance and outcome, researchers have concluded that alliance is a critical component of effective psychotherapies (Horvath et al., 2011; Miller & Mizes, 2000; Shirk et al., 2011).

Substantial debate surrounds the importance of therapeutic alliance in eating disorders (EDs). Although qualitative research has consistently indicated that individuals with EDs find their relationship with the therapist to be important to their well-being, recovery, and treatment satisfaction (e.g., Escobar-Koch, Mandlich, & Urzua, 2012), quantitative research on the relationship between the alliance and outcome in ED treatment has yielded mixed results. Multiple studies have shown that therapeutic alliance predicts outcome (e.g., Bourion-Bedes et al., 2013; Constantino, Arnow, Blasey, & Agras, 2005; Zeeck & Hartmann, 2005); yet, other studies have found little or no association (e.g., Waller, Evans, & Stringer, 2012; Zaitsoff, Doyle, Hoste, & Le Grange, 2008). Discrepant results across studies may be due to study-level differences in therapeutic approach, ED diagnosis, patient age, or drop-out.

---

$r_w = \text{weighted mean correlation}$
The importance of early alliance relative to that of early symptom change in ED treatment is also unclear. A number of studies have observed strong associations between symptom change and therapeutic alliance in the first few weeks of treatment (Brown, Mountford, & Waller, 2013b; Constantino et al., 2005), as well as early symptom change and later outcomes (Le Grange, Accurso, Lock, Agras, & Bryson, 2014; Raykos, Watson, Fursland, Byrne, & Nathan, 2013). Thus, it could be argued that the alliance is simply a by-product of early symptom change, and that alliance-outcome associations that do not account for the role of early symptom change may be spurious (DeRubeis, Brotman, & Gibbons, 2005). To the extent that a quality alliance may result from versus promote change, some have questioned whether alliance is overvalued, and whether its importance may vary by treatment type (Brown, Mountford, & Waller, 2013a).

**Possible Moderators of the Relation between Therapeutic Alliance and Outcome**

The strength of the relation between therapeutic alliance and outcome reported in prior studies may depend on a number of study-level characteristics, including therapy type, mean patient age, patient diagnosis, alliance rater, and dropout rate.

**Therapy type.** Findings regarding differences in the relationship between alliance and treatment outcome for different types of therapy have been inconclusive. In the non-ED literature, a study investigating two treatments for borderline personality disorder indicated that alliance was more important for outcome in patients receiving behavioral (i.e., dialectical behavioral therapy) versus non-behavioral (i.e., community care by experts) treatment (Bedics, Atkins, Harned, & Linehan, 2015). Conversely, one meta-analysis found that alliance was relevant to the outcome of therapy only when that therapy was relatively unstructured (i.e., non-behavioral) (Crits-Christoph et al., 1991); though other meta-analyses have not replicated this
distinction (Horvath et al., 2011). In EDs specifically, CBT researchers have questioned the relationship between alliance and outcome, with certain studies finding no relationship between alliance and outcome in CBT for anorexia nervosa (AN; e.g., Waller et al., 2012) and bulimia nervosa (BN; e.g., Raykos et al., 2013).

**Patient age.** The development of therapeutic alliance may differ in younger versus older patients. Specifically, child and adolescent patients may have limited abstract reasoning skills (Bravender et al., 2007), minimize or deny symptoms, or feel pressure from caregivers to enter treatment involuntarily (Sperry, Roehrig, & Thompson, 2009). Thus some have argued that clinicians should pay extra attention to establishing a strong alliance relative to other goals early in youth treatment (Sperry et al., 2009). In line with these suggestions, in studies of child and adolescent therapy in general, Shirk et al. (2011) found a trend for stronger alliance-outcome associations among younger patients. In contrast, there is also reason to believe that alliance-outcome associations might be less important to outcome in youth with EDs. For example, family-based treatment (FBT), which empowers parents to take charge of their child’s eating, emphasizes a strong alliance with caregivers early in treatment, which may alter the nature of the relationship between patient-rated alliance and outcome. In a meta-analysis of youth treatment studies for a variety of psychiatric disorders, the alliance-outcome association was weaker for family versus individual therapies (McLeod, 2011). While prior ED studies have separately focused on patients of different ages, none have examined patient age as a moderator of the association between alliance and outcome.

**Patient diagnosis.** Clinicians have posited differences in the overall quality of the alliance based on ED diagnosis and have speculated that treatment resistance among patients with AN may hinder the development of a positive alliance (Strober, 2004). However, multiple
studies have shown alliance to be relatively strong among patients with AN (Sly, Morgan, Mountford, & Lacey, 2013; Waller, et al., 2012). In fact, Antoniou and Cooper’s qualitative review of the relationship between alliance and outcome in EDs (2013) suggested that the alliance strongly predicted outcome for patients with AN, whereas findings for BN, binge eating disorder (BED), and subthreshold eating disorders were mixed.

**Therapeutic alliance rater.** Studies have shown differential effects depending on whether therapeutic alliance was rated by the patient, the therapist, or an independent observer. In some studies, patient and independent observer ratings of alliance have shown stronger relationships to treatment outcome than therapist ratings (Bachelor & Horvath, 1999). In the case of FBT for EDs, the alliance rating is also complicated by the presence of not only the patient but also the parents, who are expected to implement important treatment interventions. Differences between mother-rated, father-rated, and observer-rated alliance and outcome were noted in a study of FBT for AN (Ellison et al., 2012), with mother-rated alliance showing the strongest relationship to weight gain. Two different studies analyzing data from a large randomized controlled trial comparing CBT and IPT for BN (Constantino et al., 2005; Loeb et al., 2005) found that patient-rated alliance predicted outcome, whereas observer-rated alliance did not.

**Drop-out.** Drop-out is a substantial problem in ED treatment studies, with attrition rates ranging from 20-73% in inpatient and outpatient settings (Fassino, Pierò, Tomba, & Abbate-Daga, 2009). ED research reflects consistent findings from the wider alliance literature, observing that poor alliance predicts drop-out (Morlino et al., 2007; Sly et al., 2014). Given that variability in therapeutic alliance is associated with drop-out, it is possible that studies with high drop-out would show different alliance-outcome associations versus those with low drop-out.
Other variables. Other variables, including how therapeutic alliance is measured, and how treatment outcome is defined, could also impact the relation between alliance and outcome.

The Current Meta-Analysis

Primary Questions. To better understand the relationship between therapeutic alliance and treatment outcome in EDs, we conducted the first meta-analysis on this topic. Specifically, we evaluated the aggregated strength of the relationship between alliance and outcome by conducting temporal analyses of symptom change. Thus change in ED symptoms (i.e., weight, ED behaviors, and ED cognitions) over the course of treatment was our definition of outcome in the current meta-analysis. A significant correlation between therapeutic alliance measured at some point in treatment and a treatment outcome, with no covariates in the model, does not demonstrate that the alliance is a causal mechanism of symptom change. In this scenario, there is no control over (1) temporal precedence (i.e., that alliance promotes change measured after alliance measurement) and (2) the potential role of change occurring prior to alliance measurement (i.e., the notion that the alliance may be epiphenomenal to symptom reduction that has already occurred). To better assess whether alliance changes independently from, or in interaction with, symptom change, we needed to analyze the alliance-outcome association across multiple points in treatment (with time lags to address temporal sequencing) and account for the role of prior symptom change (Brown et al., 2013a). Because the data required to perform temporal analyses were not included in published articles, our team contacted the corresponding authors of all studies meeting inclusion criteria to acquire the necessary data. Studies whose author(s) responded to our request and were able to retrieve the needed data were included in our meta-analysis (see Method).
Our analyses addressed four questions. The first three concerned the relationship between symptom change and later therapeutic alliance at different points in the treatment, and the fourth addressed the relationship between early alliance and later symptom improvement: (1) Does early change in symptoms (i.e., early improvement) predict early/mid alliance? (2) Does mid-to-end of treatment change in symptoms predict alliance at the end of treatment? (3) Does change in symptoms across the entirety of treatment predict alliance at the end of treatment? (4a) Does early/mid alliance predict subsequent change in symptoms? And (4b) Do early/mid alliance and early symptom change each predict unique variance in subsequent change in symptoms (i.e., question 4b is an extension of question 4a, but controlling for symptom change)?

Potential moderators. In addition to evaluating the strength of the relationship between therapeutic alliance and symptom change, we explored potential moderators (i.e., study-level characteristics that could explain variance in effect sizes). Based on prior literature, we hypothesized that study-level characteristics including therapy type, patient age, patient diagnosis, alliance rater, and study drop-out rate would contribute to differences in effect size.

Method

Inclusion Criteria

We set the following inclusion criteria for studies in our meta-analysis: (a) comprised a sample of patients diagnosed with one or more ED(s), including AN, BN, BED, EDNOS, or sub-threshold diagnoses; (b) included a measure of therapeutic alliance at one or more time points to one or more sample groups during the study (e.g., Working Alliance Inventory, Helping Alliance Questionnaire, Helping Relationship Questionnaire, or California Psychotherapy Alliance Scales); (c) conducted and reported at least one statistical analysis of the relationship between alliance and a primary treatment outcome variable (e.g., weight, binge/purge frequency, self-report or interview measure of ED psychopathology); (d) was not a case report; (e) was
published between the dates of January 1978 (i.e., the date of the first ED treatment study to report alliance-outcome data) and January 2014 (f) was published in English; and (g) did not utilize data already reported in another study included in the meta-analysis. All studies meeting each of these requirements were retained for further inspection, while the remaining studies were assigned reasons for exclusion.

**Selection of Studies**

To identify relevant studies, we conducted a computer-based search using PsycINFO, PubMed, and Academic Search Premier. We also searched ProQuest Dissertations and Theses specifically to locate unpublished studies. We identified search terms for alliance and EDs in the controlled vocabulary of each database. For example, in PsychINFO, the terms for therapeutic alliance were alliance, therapeutic alliance, treatment alliance, helping alliance, working alliance, psychotherapy relationship, therapeutic relationship, therapeutic bond, helping relationship, and patient therapist relationship. The PsychINFO terms for EDs were eating disorders, anorexia, bulimia, binge eating disorder, EDNOS, and eating disorder not otherwise specified. We then searched each database for studies that were tagged with both alliance and EDs controlled-vocabulary terms. Lastly, we mined the reference section of eight review articles relevant to alliance in EDs which we identified via the initial electronic database search (Fassino & Abbate-Daga, 2013; Manlick, Cochran, & Koon, 2013; Martin et al., 2011; Shirk et al., 2011; Vitousek & Watson, 1998; Vocks et al., 2010; Westwood & Kendal, 2012; Wilson, 2011) for any additional relevant studies that may have been missed.

The electronic database search combined with the hand search of the review articles resulted in an initial candidate study pool of 767 studies. These studies were then reduced in a stepwise fashion by two independent coders (the first and second authors), as described in the
The two coders first screened each abstract, applying the a priori inclusion and exclusion criteria. Of the initial pool of abstracts, 48 studies were retained for full-text screening. The inter-rater reliability between the two coders for abstract screening was acceptable with a kappa = .67, p < .01. When the coders’ ratings diverged, they were discussed until consensus was achieved. The two coders then independently screened the full text of the 48 retained studies. This process resulted in a reduced pool of 27 eligible studies. The inter-rater reliability between the two coders for the full-text screening was substantial with a kappa = .76, p < .01. These studies were then back-searched using Google Scholar in order to locate any additional studies referencing those already included in the pool. None of the new studies located during this final step met inclusion criteria.

**Requests for Additional Data**

In order to perform the temporal analyses necessitated by our research questions, our team contacted the corresponding authors of all 27 eligible studies to request additional—typically unpublished—data that would be required. We formulated individualized email requests for each author(s) based on data available from the published report. We received data from the participating studies between May and October of 2014.

Of the 27 authors who received email requests, 20 responded positively, and were able to forward all necessary data in a usable format for the proposed temporal analyses. Only six authors responded negatively to our request, citing that they either (1) did not wish to participate (Ellison et al., 2012; Hildebrandt, Loeb, Troupe, & Delinsky, 2012; Hoffman, 2006); (2) were not able to provide the requested data because it was inaccessible (Treasure et al., 1999; Wilson et al., 1999); or (3) did not collect data from the needed time points (Hartmann, Orlinsky, Weber,
META-ANALYSIS OF THE RELATION BETWEEN THERAPEUTIC ALLIANCE

Sandholz, & Zeeck, 2010). Finally, one dissertation (Leonard, 2007) could not be included because we could not locate contact information for the corresponding author.

Measures of Outcome (i.e., ED Symptoms) and Therapeutic Alliance

**Outcome (i.e., ED symptoms).** In the 20 studies included in our meta-analysis, investigators measured improvement in ED symptoms with several relevant measures including body mass index (BMI), weight, percent ideal body weight, binge/purge frequency, vomiting frequency, body checking frequency, Eating Disorder Examination-Questionnaire (EDE-Q), Outcome Questionnaire-45.2, and urge to restrict.

**Therapeutic alliance.** In the 20 studies included in our meta-analysis, investigators measured therapeutic alliance with nine different scales: Agnew Relationship Measure; Bern Post-Session Reports for Patients; California Psychotherapy Alliance Scales; Helping Alliance Questionnaire; Helping Relationship Questionnaire; System for Observing Family Alliances; Scale for the Multiperspective Assessment of General Change Mechanisms in Psychotherapy; Treatment Satisfaction Scale; and Working Alliance Inventory. We broadly defined early alliance as the point in treatment when alliance was first measured. For most studies, this point in treatment was between sessions 1 and 5 with the exception of one naturalistic longitudinal study that first measured the alliance at 6 months of treatment, which was approximately mid-way through therapy (average length of treatment, M = 18 ± 19 months; Paulson Karlsson, Clinton, & Nevonen, 2013). We defined mid alliance as the point at which the alliance rating occurring closest to the midpoint of treatment. For most studies, mid alliance was measured between session 6 and 12. We defined late alliance as the alliance rating at the end of treatment. This was always the last alliance measurement taken; timing varied across studies.

Levels of Each Moderator Variable
We examined the following variables as possible moderators of the alliance-outcome effect size, classifying each study as falling into one of the following levels on each moderator.

**Therapy type.** We coded therapy type as a categorical variable with five categories: behavioral weight-loss therapy (BWLT), CBT, FBT, individual-focused therapy, or multiple therapies. The BWLT category comprised a manualized behavioral treatment following the tetrahydrolipstatin-based weight loss manual that focuses on balanced nutrition and physical activity to promote weight loss (Margraf, 2000; Munsch, Biedert, & Keller, 2003). The CBT category included manualized treatments that employ both cognitive and behavioral strategies to promote eating-disorder symptom change. The FBT category included a manualized treatment that empowers parents to effect change in their child’s eating-disorder symptoms (Lock, Le Grange, Agras, & Dare, 2001). The individual-focused therapy category included therapies that fostered the development of insight in related areas, but did directly encourage change in eating-disorder symptoms, including adolescent-focused therapy (AFT), IPT, and supportive psychotherapy (SPT). The multiple therapies category included studies in which participants received two or more different types/modes of therapy either simultaneously or consecutively (e.g., a mixture of inpatient, day-patient, outpatient, individual, group, and/or family therapies [Paulson Karlsson et al., 2013], a treatment combining individual therapy and a supportive program aimed at improving weight and eating behaviors [Bourion-Bedes et al., 2013]).

**Mean age.** We recorded the mean age of each study sample as a continuous variable. When there was more than one sample in a study (e.g., a randomized controlled trial), we recorded the mean age for each sub-sample. However, when the mean age for each subsample was not reported and there was no statistically significant difference in mean age between the sub-samples, the mean age for the total sample was used for both subsamples.
**ED diagnosis.** We coded ED diagnosis as a categorical variable with four categories: AN, BN, BED, or multiple. A sample was coded as multiple when the sample was composed of people with different ED diagnoses.

**Therapeutic alliance rater.** We coded therapeutic alliance rater as a categorical variable with two categories: patient-rated or independent observer-rated. In instances where data from more than one rater of the alliance was included in a study (e.g., patient-rated and parent-rated alliance or patient-rated and therapist-rated alliance), we chose to use the patient-rated alliance or the independent observer-rated alliance (if patient-ratings were not provided) because patient ratings and independent observer ratings have shown stronger associations to treatment outcome than parent or therapist ratings of the alliance (Bachelor & Horvath, 1999; Horvath et al., 2011). We did not have any studies in our pool that only collected therapist- or parent-rated alliance data.

**Study drop-out rate.** We recorded study drop-out rate as a continuous variable. When there was more than one sample in a study (e.g., a randomized controlled trial), each sub-sample was assigned the same study drop-out rate, unless drop-out was reported individually for each sub-sample.

**Effect Size Information**

We used the standardized regression coefficient (β) to evaluate effect size for each of our four meta-analytic research questions. Rather than extracting effect-size data from the original papers, we obtained more detailed information (i.e., descriptive statistics and correlations) directly from the authors of each study—this was necessary because many studies did not report the information needed to calculate temporal effect sizes. When there was missing data in the summary statistics, we used pairwise deletion in the analyses required to obtain the effect sizes of interest to increase sample size and thus power. When there was no missing data reported in
the summary statistics, analyses required to obtain the effect sizes of interest were based on the total sample.

To facilitate comparison across therapy types within each study, we calculated separate effect sizes of the alliance-outcome relation for each treatment arm. We then calculated our own effect sizes, standard errors (SE), 95% confidence intervals (CI), and p-values using individual multiple linear regression analyses in SPSS. In all analyses, we coded treatment outcome variables such that higher positive scores indicated greater symptom change (e.g., increased BMI in AN trials, decreased binge/purge frequency in BN trials) and stronger alliance. Some studies utilized multiple measures of the same construct—either alliance or ED symptoms. When a particular measure included more than one subscale that could be combined into a global score (e.g., EDE-Q), we used the global score to calculate the effect size for the relation between alliance and outcome. When a measure contained subscales that could not be combined to achieve a total score (e.g., Working Alliance Inventory), we averaged the effect sizes for the outcome-alliance relation for each subscale, to obtain an average effect size for that study (as in Thomas, Vartanian, & Brownell, 2009).

For the first question (i.e., Does early symptom change predict early/middle alliance?), the regression analysis included (1) ED symptoms at baseline, and (2) change in symptoms from baseline to when alliance was first measured, as predictors of the first measure of alliance. Thus, the standardized regression coefficient indexed the relationship between early symptom change and alliance, controlling for baseline symptom level. For the second question (i.e., Does middle to end of treatment symptom change predict later alliance?), the regression analysis included (1) ED symptoms when alliance was first measured and (2) change in symptoms from when alliance was first measured to the end of treatment as predictors of alliance at the end of treatment.
Therefore, the standardized regression coefficient indexed the relationship between change in treatment outcome and alliance at the end of treatment, controlling for symptom level at the time of first alliance measurement. For the third question (i.e., Does symptom change across treatment predict later alliance?), the regression analysis included (1) ED symptoms at baseline and (2) change in symptoms from baseline to end of treatment as predictors of alliance at the end of treatment. Thus, the standardized regression coefficient indexed the relationship between change in treatment outcome from baseline to end of treatment and alliance at the end of treatment, controlling for baseline symptom level. For the fourth question (i.e., Does early/mid alliance predict subsequent symptom change?), the regression analysis included (1) alliance and (2) ED symptoms when the alliance was first measured as predictors of change in treatment outcome from when the alliance was first measured to the end of treatment. Therefore, the standardized regression coefficient indexed the relationship between early/mid alliance and subsequent symptom change, controlling for symptom level at the time of alliance measurement. We also conducted a second regression analysis to examine whether early/mid alliance predicts subsequent symptom change above and beyond early symptom change. Thus, the regression analysis included (1) the first measure of alliance and (2) change in symptoms from baseline to when alliance was first measured as predictors of change in treatment outcome from when the alliance was first measured to the end of treatment. The standardized regression coefficient indexed the relationship between early/mid alliance and subsequent symptom change while statistically controlling for early symptom change.

Meta-analytic Procedures
For each research question, we pooled relevant effect sizes, weighted by their inverse-variance \((1/SE^2)\). The SE of each effect size \((\beta)\) was calculated using the formula provided by Cohen, Cohen, West, & Aiken (2003; also see Card, 2013):

\[
SE_{\beta_i} = \sqrt{\frac{1 - R^2_i}{n - k - 1}} \sqrt{\frac{1}{1 - R^2_T}}
\]

where \(R^2_T\) is the variance explained in the dependent variable by the independent variables in the regression model, \(R^2_i\) is the variance explained in the independent variable of interest by the remaining independent variables in the regression model, \(n\) is the sample size, and \(k\) is the number of independent variables in the regression model. We interpreted the magnitude of each effect size according to Cohen’s (1988) conventions for correlation coefficients, where .10 is small, .30 is moderate, and .50 is large.

To allow us to generalize our results beyond the current sample, we used a random-effects model. We assessed publication bias using Egger’s test (Egger, Davey, Schneider, & Minder, 1997), which examines the presence of asymmetry in a funnel plot of effect sizes. For each research question, we also assessed whether the effect sizes were more heterogeneous than expected by sampling variability alone using the test of heterogeneity (Q-statistic). When there was evidence of heterogeneity, we used the \(I^2\) statistic to quantify the extent of heterogeneity. We then conducted follow-up moderator analyses using random-effects analogue to ANOVA for categorical moderators, and random-effects meta-regression for continuous moderators. When one or more statistically significant moderators were at least moderately correlated, we conducted a meta-regression analysis in which we controlled for their shared association. We conducted all analyses using Comprehensive Meta-Analysis Version 2.0 software program.
(Borenstein, Hedges, Higgins, & Rothstein, 2005) except for the meta-regressions which we conducted using SPSS macros (Lipsey & Wilson, 2001).

Results

(1) Does early symptom change predict early/mid alliance?

Omnibus test. A total of 18 independent effect sizes from 14 different reports evaluated the relationship between early symptom change and early/mid therapeutic alliance (Table 1). For most reports, early/mid alliance was measured between sessions 3 and 10 of treatment; one naturalistic longitudinal study first measured the alliance after 6 months of treatment, which was approximately mid-way through therapy in this particular design (average length of treatment, M = 18 ± 19 months) (Paulson Karlsson et al., 2013). As expected, greater positive change in symptoms (i.e., greater improvement) from baseline to when the alliance was first measured predicted stronger early/mid alliance, $\beta = .19, 95\% \text{ CI } [.11, .28], z = 4.38, p < .0001$. The magnitude of the mean effect size was small-to-moderate and there was no evidence of publication bias, Egger's regression intercept = .02, $t (16) = .06, p = .95$.

Moderator analyses. In addition, the effect sizes were heterogeneous, $Q (17) = 28.41 \ p = .04$, but the extent of heterogeneity was low, $I^2 = 40.16$. In follow-up moderator analyses, study drop-out rate was associated with effect sizes at trend-level, $Q (1) = 3.65, p = .06$. Specifically, studies with higher drop-out rates had larger effect sizes, slope = .01, 95% CI [-.0002, .014], $z = 1.91, p = .06$. To further evaluate this finding, we examined the mean effect size at high (+1 SD) and low (-1 SD) levels of study drop-out rate (weighted M = 14.60% drop-out rate, SD = 5.19). At 1 SD above the mean of study drop-out rate, the effect size was small-to-moderate and statistically significant, $\beta = .21, 95\% \text{ CI } [.13, .30], z = 4.91, p < .001$. Likewise, at 1 SD below the mean of study drop-out rate, the effect size was small and statistically significant, $\beta = .14,$
95% CI [.04, .24], \(z = 2.84, p = .004\). Taken together, these findings indicate a positive linear relationship between the magnitude of the effect sizes and study drop-out rate. None of the remaining moderators were statistically significant (Table 2).

(2) Does mid-to-end of treatment change in symptoms predict later alliance?

Omnibus test. A total of ten independent effect sizes from eight different reports evaluated the relationship between mid-to-end of treatment symptom change and later therapeutic alliance (see Table 3). Alliance in all reports was measured at the end of treatment (i.e., at the final treatment session). Results for the overall mean effect size indicated that change in symptoms (i.e., improvement) from when early/mid alliance was measured until the end of treatment was not related to later alliance, \(\beta = .10, 95\% \text{ CI }[-.04, .24], \(z = 1.46, p = .15\). The mean effect size was not statistically significant and there was no evidence of publication bias, Egger’s regression intercept = .02, \(t (8) = .02, p = .97\).

Moderator analyses. Because the effect sizes were homogenous, \(Q (9) = 2.79, p = .97\), we did not evaluate potential moderators.\(^2\)

(3) Does change in symptoms across treatment predict later alliance?

Omnibus test. A total of 18 independent effect sizes from 12 different reports evaluated the relationship between change in symptoms across treatment and later alliance (Table 4). In almost all reports, later alliance was measured at the end of treatment. As expected, greater positive change in symptoms (i.e., improvement) across each study’s duration predicted greater subsequent alliance, \(\beta = .17, 95\% \text{ CI }[.06, .29], \(z = 2.96, p = .003\). The mean effect size was

\(^2\) Although moderator analyses are often underpowered in meta-analyses comprising a relatively small number of studies, we chose to remain conservative by following the recommendations of Cooper, Hedges, & Valentine (2009) and Lipsey and Wilson (2001) not to evaluate moderators following a non-significant omnibus test.
small-to-moderate and there was no evidence of publication bias, Egger’s regression intercept = .81, t (16) = .94, p = .36.

Moderator analyses. Effect sizes were homogenous, Q (17) = 24.17, p = .12, so we did not evaluate moderators.

(4a) Does early/mid alliance predict subsequent symptom change?

Omnibus test. A total of 19 independent effect sizes from 15 different reports evaluated the relationship between early/mid therapeutic alliance and change in symptoms from when early/mid alliance was measured to the last time-point of data on symptoms available in each report (see Table 5). For almost all reports, the last time-point of data on symptoms was the end of treatment; in one naturalistic longitudinal study, alliance was assessed after 6 months of treatment (Paulson Karlsson et al., 2013). As expected, greater early/mid alliance predicted greater subsequent symptom change, β = .13, 95% CI [.05, .22], z = 3.10, p = .002. The magnitude of the mean effect size was small and there was no evidence of publication bias, Egger’s regression intercept = .48, t (17) = .67, p = .51.

Moderator analyses. The effect sizes were heterogeneous, Q (18) = 26.55, p = .09, and the extent of heterogeneity was low, I² = 32.20. As such, we evaluated potential moderators. Therapy type was related to effect size, Q (4) = 10.61, p = .03. Specifically, greater early/mid alliance predicted greater subsequent positive change in treatment outcome for studies involving multiple therapies (β = .18, 95% CI [.05 .32], z = 2.70, p = .007, k = 6); individual-focused therapies (β = .21, 95% CI [.05, .37], z = 2.56, p = .01 k = 4); and FBT (β = .31, 95% CI [.08, .54], z = 2.62, p = .009, k = 3). In contrast, early/mid alliance was not related to subsequent

---

3 While Paulson Karlsson et al. (2013) also measured alliance 36 months after the start of treatment, we did not include those data in the current meta-analysis because the length of follow-up at the final time point of this longitudinal study differed so greatly from the other included studies, which were primarily much briefer randomized controlled trials.
positive change in treatment outcome for studies involving BWLT ($\beta = -.05$, 95% CI [-.20, .11], $z = -.59$, $p = .56$, $k = 2$), and CBT ($\beta = -.02$, 95% CI [-.25, .21], $z = -.19$, $p = .85$, $k = 4$). A follow-up meta-regression analysis evaluated mean differences in effect sizes as a function of therapy type. In the meta-regression, we used CBT as the reference group for therapy type (BWLT was not suitable to serve as the reference group because there were only two studies). Therapy type accounted for 43% of the variance in the effect sizes, $R^2 = .43$, $Q (4) = 10.35$, $p = .04$. The mean effect size for studies involving FBT were larger than the mean effect size for studies involving CBT, $B = .31$, $z = 2.12$, $p = .03$. Likewise, there was a non-statistically significant trend indicating that the mean effect for studies involving multiple therapies tended to be larger than the mean effect size for studies involving CBT, $B = .18$, $z = 1.78$, $p = .07$. Similarly, there was also a non-statistically significant trend indicating that the mean effect size for studies involving individual-focused therapies tended to be larger than the mean effect size for studies involving CBT, $B = .21$, $z = 1.76$, $p = .07$. Also, the mean effect size for studies involving BWLT did not differ from the mean effect size for studies involving CBT, $B = -.04$, $z = -.37$, $p = .71$, although in this case the size and direction of the effect did not reflect a similar pattern to the other variables, i.e., it was more similar to the results for CBT. In sum, greater early/mid alliance predicted greater subsequent positive change in treatment outcome for studies involving FBT, multiple therapies, and individual-focused therapies relative to studies involving CBT where there was no such effect. None of the remaining moderators were related to variability in the effect sizes (Table 2).

(4b) Does early/mid alliance predict subsequent symptom change above and beyond early symptom change?
Omnibus test. A total of 15 independent effect sizes from 11 different reports allowed us to evaluate the relationship between early/mid therapeutic alliance and change in symptoms from when early/mid alliance was measured to the last time-point of data on symptoms available in each report while statistically controlling for early symptom change (Table 6). For almost all reports, the last time-point of data on symptoms was at end of treatment; however, for one study, the last time-point of data on symptoms was at 6-month follow-up (Paulson Karlsson et al., 2013). The mean effect size was not statistically significant, $\beta = .07$, 95% CI [-.04,.17], $z = 1.26$, $p = .21$, and there was no evidence of publication bias, Egger’s regression intercept = .09, $t (13) = .09$, $p = .93$.

Moderator analyses. The effect sizes were heterogeneous, $Q (14) = 23.15$, $p = .058$, and the extent of heterogeneity was low, $I^2 = 39.52\%$. Thus, we evaluated potential moderators. Sample mean age was related to effect size, $Q (1) = 16.20$, $p < .01$. Specifically, studies with older samples had smaller effect sizes relative to studies with younger samples, $B = .03$, $z = -4.03$, $p < .001$. To further evaluate this finding, we examined the mean effect size at high (+1 SD) and low (-1 SD) levels of sample mean age (weighted M = 22.08 years old, SD = 5.94). At 1 SD above sample mean age, the effect size was small and was not statistically significant, $\beta = -.10$, 95% CI [-.20,.01], $z = -1.71$, $p = .09$. This finding indicates that early/mid alliance did not predict change in symptoms from when the early/mid alliance was measured to the end of treatment above and beyond early symptom change in studies with older patients. However, at 1 SD below the sample mean age, early/mid alliance predicted greater improvement in symptoms from when the early/mid alliance was measured to the end of treatment above and beyond early symptom change in studies with younger patients, $\beta = .22$, 95% CI [.11,.33], $z = 3.98$, $p = .0001$. The magnitude of the effect size was small-to-moderate.
ED diagnosis was also related to the effect sizes, $Q (2) = 6.10, p = .04$. Specifically, the mean effect size was statistically significant and small for studies with samples of AN ($\beta = .16$, 95% CI [.04, .27], $z = 2.57, p = .01$), but was not significant for studies with samples of BN ($\beta = -.10$, 95% CI [-.26, .06], $z = -1.17, p = .24$) and studies with mixed ED samples ($\beta = .06$, 95% CI [-.18, .30], $z = .49, p = .62$). In short, early/mid alliance predicted greater improvement in symptoms from when the early/mid alliance was measured to the end of treatment above and beyond early symptom change in studies with samples of AN. None of the remaining moderators were statistically significant (Table 2).

Sample mean age ($R^2 = .53, p = .04$) and ED diagnosis (Cramer’s $V = .52$, $p < .001$) were both moderately associated with therapy type. However, sample mean age and ED diagnosis were not related ($R^2 = .14, p = .33$). Thus, we conducted a follow-up meta-regression to examine whether sample mean age and ED diagnosis remained statistically significant predictors of effect size while controlling for shared variance with therapy type. In the meta-regression, we used AN as the reference group for ED diagnosis and individual-focused therapies as the reference group for therapy type. Mean age, ED diagnosis, and therapy type together accounted for 88% of the variance in the effect sizes, $R^2 = .88$, $Q (6) = 20.42, p = .002$. Sample mean age accounted for unique variance in the effect sizes above and beyond ED diagnosis and therapy type, $B = -.03, z = -3.01, p = .003$. In contrast, differences in ED diagnosis did not account for unique variance in the effect sizes above and beyond mean age and therapy type. Differences in therapy type did not account for variance in the effect sizes. In sum, findings indicated that early/mid alliance predicted greater subsequent improvement in symptoms above and beyond early symptom change in studies with younger patients, regardless of their ED diagnosis and therapy type.

**Discussion**
Although ED clinicians have long stressed the role of therapeutic alliance in facilitating symptom change, ED researchers studying behavioral treatments have instead stressed the importance of early symptom change for promoting therapeutic alliance and have debated the relative and temporal influences of these two factors on each other and outcome. Our meta-analysis of 20 ED treatment studies, examining the relations between symptom change and alliance across time and samples, supports a reciprocal relationship between symptom change and alliance. In addition, our analyses are unique in that they are the first in ED treatments to identify that the relative importance of therapeutic alliance for treatment outcome may differ across treatment type, patient age, and patient diagnosis. Interestingly, alliance rater (independent rater versus patient) did not impact effect sizes. Further, the current study succeeded in connecting multiple well-known research groups in the field of EDs from across the globe, representing data from nine different countries. We evaluated four distinct research questions, finding statistically significant results for three of the four, with all effect sizes being in the hypothesized direction.

We identified the strongest association between symptom change and subsequent alliance, specifically a small-to-moderate sized relationship between early symptom change and early/mid alliance (question 1), as well as a small-to-moderate relationship across-treatment symptom change and subsequent alliance (question 3). This relationship between symptom change and alliance early in therapy was not moderated by treatment type, ED diagnosis, or other factors, and therefore should be assumed to hold across all levels of these moderator variables. The finding that positive symptom change strengthens therapeutic alliance is consistent with evidence from other psychological disorders, including depression (Tang & DeRubeis, 1999).
However, additional analyses also supported the temporal role of the early alliance in facilitating later symptom change. Results for question 4a (Does early/mid alliance predict subsequent symptom change?) indicated that early/mid alliance ratings also predicted subsequent changes in outcome. Although differences were noted in the relationship between early alliance and later symptom change between different types of treatment, these results were only significant at the trend level, and should therefore be interpreted with caution. The results of moderator analyses supported the role of early alliance in predicting later symptom-change for individual-focused therapies (e.g., IPT, AFT, and SPT), FBT, and multiple therapies; but not for CBT or BWLT. Further, meta-regression to explore individual comparisons indicated that the differences between CBT and other treatments, excepting BWLT, were particularly strong. These results are very interesting in light of the importance of early symptom change to outcome in CBT (Brown et al., 2013b). It is possible that the alliance is particularly critical in therapies where it is viewed and cultivated as an agent of change; however, further research is needed to confirm this.

Unique analyses compared the relative strength of the associations between treatment outcome and (a) early therapeutic alliance, and (b) early symptom change, including moderator analyses to explore potential differences according to patient age and patient diagnosis. The results indicated that the early alliance was significantly related to subsequent symptom change for younger patients and for patients with AN, but not for older patients or those with other ED diagnoses. Further analyses controlling for the correlations between patient age, ED diagnosis, and treatment type, found that patient age produced the only statistically significant effect after controlling for ED diagnosis and therapy type, indicating that it was a particularly important predictor of a stronger association between the early alliance and outcome. These findings reflect
the observations of some alliance researchers outside the field of EDs (Shirk et al., 2011), as well as clinicians who treat adolescents. Importantly, age was a significant moderator even after controlling for treatment type (i.e., individual versus family-based), suggesting that extra attention may need to be paid to the alliance relative to other goals early in treatment for younger patients with EDs (Sperry et al., 2009), regardless of theoretical orientation. Of course, given that age was examined as a study-level (rather than individual-level) moderator in this meta-analysis, we can only draw conclusions about studies that recruited younger patients, rather than any specific youth patient, or youth patients in general.

Our findings also suggested that drop-out rate should be considered when interpreting the size and significance of the relation between symptom change and early alliance ratings. Results indicated that when drop-out was low, symptom change showed a smaller relationship to early/mid alliance ratings, whereas when it was high, early improvement more strongly predicted early/mid alliance ratings. Patients drop out of studies for a wide range of reasons and at various points in treatment (both early and late). Studies that retain patients who are otherwise likely to drop out may include patients with a variety of factors influencing both alliance and symptom change, introducing other sources of variance and error into the symptom change/alliance relationship. It is also possible that patients who drop out of treatment tend to have lower levels of the alliance at the outset or are initially less symptomatic. Thus, it could be argued that drop-out, outcome, and therapeutic alliance are confounded. This possibility should temper the interpretation that early symptom change predicts later alliance as well. A more nuanced study of the drop-out/alliance/outcome relationships in ED samples would help to clarify these questions.

Within the 20 studies included in this meta-analysis, nine different measures of therapeutic alliance were used. Due to the diverse range of alliance measures, it was not possible
to include this variable in our moderator analyses. Research indicates that the shared variance among the numerous measures of therapeutic alliance is less than 50%, even among the four so-called “core” measures (i.e., Working Alliance Inventory, Helping Alliance Questionnaire, California Psychotherapy Alliance Scale, and Vanderbilt Psychotherapy Process Scale) (Horvath, 2009). This suggests that these scales may all be measuring slightly different constructs. Future research should be designed to investigate if and how the type of alliance rating measure used may affect the resulting alliance-outcome associations.

This study has limitations that should be noted. First, our sample of included studies was relatively small. Although there has been an increased focus on therapeutic alliance in recent years, there are still relatively few treatment studies within the ED field that have collected both alliance and outcome data. Moreover, of the studies that have collected such data, most only assess these variables a few times across treatment. In order to truly begin to untangle this issue, alliance and outcomes should be measured repeatedly, from session 1 to end of treatment. Our findings, combined with others from the ED field (i.e., Tasca & Lampard, 2012), suggest that alliance and outcomes are not static constructs. They change over time and it is quite possible that it is the change in these constructs that is key. Moreover, although our meta-analysis provided the unique opportunity to evaluate changes in both alliance and symptoms over time, the temporal precedence of one over the other does not necessarily imply causality.

Further, despite our best attempts to locate all relevant studies and contact all corresponding authors, there remained a number of applicable studies that were excluded from our meta-analyses because of (1) difficulties contacting the corresponding author(s), or (2) the inability of corresponding author(s) to retrieve the needed data. The inclusion of these missing data could have yielded different results. Second, with regard to our moderator analyses, it is
important to note that study sample sizes (k) for many of these analyses were quite small, and therefore, results from these analyses should be interpreted with caution. This is particularly true of the moderator analyses involving therapy type. Third, the majority of the included studies were composed of Caucasian females (~90%), which greatly reduces the generalizability of our results to only one subset of the population receiving ED treatment. It is not yet known whether these results would apply to males and/or patients from ethnically diverse backgrounds. In fact, one meta-analysis investigating the moderating effects of the presence of racial/ethnic minorities on the strength of the alliance-outcome association, found that the percentage of overall minorities (particularly African Americans) attenuated the alliance-outcome association (Flückiger et al., 2013). Unfortunately, due to largely homogenous study samples in terms of race and gender and a lack of data regarding patient comorbidities (e.g., substance use disorders), we were unable to investigate the moderating impact of these variables. Fourth, other patient variables (e.g., personality characteristics, attachment style) and therapist characteristics (e.g., gender, experience level) that may impact both alliance and outcome were not measured in a sufficient number of studies to be included as potential moderators. A final limitation of the current meta-analysis is that it was impossible to exclude all third-variable confounds. For instance, it is plausible that patient characteristics not accounted for in our analyses, such as high interpersonal functioning, patient level of insight, or patient motivation or expectancies for change, are associated with both greater alliance and outcome (Jones, Lindeklede, Lübeck, & Clausen, 2015).

Conclusions

Overall, the bidirectional relationship between therapeutic alliance and outcome found in our meta-analysis strongly suggests the critical value of both early and sustained symptom change, as well as the patient-therapist relationship in this clinically challenging population.
Symptom improvement was shown to predict subsequent alliance both early in and across the span of treatment, irrespective of treatment type, patient age, or ED diagnosis. Differences in the strength of the relationship between the early alliance and treatment outcome were observed for different treatments, with CBT and BWLT showing weaker associations than other treatment types. Multivariate analyses examining the relative strength of associations between early alliance and later outcome controlling for early symptom change, and examining differences in these relationships according to patient age and patient diagnosis, found that early symptom change accounts for a moderate portion of observed associations between the early alliance and outcome. Analyses indicated that for older patients and those with BN, BED, and mixed/subclinical diagnoses, attention to early symptom change may yield the most benefit for both the early alliance and eventual treatment outcome. However, results of these analyses indicated that younger patients may show specific benefit from additional attention to the early alliance, which showed associations with outcome even when early symptom change was taken into account. These results support a more fine-grained and complex approach to research concerning the inter-relationships between symptom improvement, alliance, and treatment outcome, with attention paid to possible differences in these relationships according to treatment approach and patient factors. Further research is needed to determine the extent to which the bidirectional relationship between therapeutic alliance and symptom change and its attendant moderators is unique to EDs, or more broadly applicable across psychiatric disorders.
References

References marked with an asterisk indicate studies included in the meta-analysis.


alliance, motivation, and behaviour change. Eating Behaviors, 14, 119–123.
doi.org/10.1016/j.eatbeh.2013.01.007


Records identified through electronic database search (n = 959)  

Records after duplicates removed (n = 787)  

Records excluded (n = 739)  

Records screened (n = 787)  

Full-text articles excluded for not meeting inclusion criteria (n = 21)  

Full-text articles assessed for eligibility (n = 48)  

Studies included in quantitative synthesis (meta-analysis) (n = 20)  

Full-text articles excluded for other reasons (e.g., unable to locate author for additional data, author(s) were unable to present needed data for analyses) (n = 7)
META-ANALYSIS OF THE RELATION BETWEEN ALLIANCE

Figure 2a. Results for question 1. Does early change in symptoms (i.e., early improvement) predict early/mid treatment alliance? \( \beta = .19, p < .0001^* \)

Figure 2b. Results for question 2. Does mid-to-end of treatment change in symptoms predict alliance at the end of treatment? \( \beta = .10, p = .15 \)

Figure 2c. Results for question 3. Does end of treatment symptom change predict later alliance? \( \beta = .17, p = .003^* \)

Figure 2d. Results for question 4a. Does early/mid treatment alliance predict subsequent symptom change? \( \beta = .13, p = .002^* \)

Figure 2e. Results for question 4b. Does early/mid alliance predict subsequent symptom change above and beyond early symptom change? \( \beta = .07, p = .21 \)

Figure 2. Forest plots for all meta-analytic research questions.
## META-ANALYSIS OF THE RELATION BETWEEN ALLIANCE

### Table 1. Question 1: Does early symptom change predict early/mid alliance?

<table>
<thead>
<tr>
<th>Report</th>
<th>N</th>
<th>Mean age</th>
<th>DX</th>
<th>Therapy setting</th>
<th>Therapy type/mode</th>
<th>Alliance rater</th>
<th>Session/of Total</th>
<th>Study dropout (%)</th>
<th>Alliance rating measure</th>
<th>Effect size information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bourion-Bedes et al. (2013)(A)</td>
<td>66</td>
<td>15.30</td>
<td>AN</td>
<td>Inpatient</td>
<td>Multi/IND</td>
<td>PA</td>
<td>3/VAR</td>
<td>0</td>
<td>HAQ</td>
<td>-.01(.13)</td>
</tr>
<tr>
<td>Bourion-Bedes et al. (2013)(B)</td>
<td>42</td>
<td>15.30</td>
<td>AN</td>
<td>Outpatient</td>
<td>Multi/IND</td>
<td>PA</td>
<td>3/VAR</td>
<td>0</td>
<td>HAQ</td>
<td>.19(.17)</td>
</tr>
<tr>
<td>Brown et al. (2013)</td>
<td>35</td>
<td>25.70</td>
<td>AN</td>
<td>Inpatient</td>
<td>Multi/IND</td>
<td>PA</td>
<td>6/30-40</td>
<td>32.31</td>
<td>WAI</td>
<td>.46(.19)</td>
</tr>
<tr>
<td>Constantino et al. (2005)(A)</td>
<td>75</td>
<td>28.10</td>
<td>BN</td>
<td>Outpatient</td>
<td>CBT/IND</td>
<td>PA</td>
<td>12/19</td>
<td>25.91</td>
<td>HAQ</td>
<td>.54(.19)</td>
</tr>
<tr>
<td>Constantino et al. (2005)(B)</td>
<td>82</td>
<td>28.10</td>
<td>BN</td>
<td>Outpatient</td>
<td>IPT/IND</td>
<td>PA</td>
<td>12/19</td>
<td>25.91</td>
<td>HAQ</td>
<td>.40(.12)</td>
</tr>
<tr>
<td>Forsberg et al. (2013)(A)</td>
<td>40</td>
<td>14.80</td>
<td>AN</td>
<td>Outpatient</td>
<td>AFT/IND</td>
<td>IO</td>
<td>3-5/32</td>
<td>17.36</td>
<td>WAI</td>
<td>-.05(.17)</td>
</tr>
<tr>
<td>Forsberg et al. (2013)(B)</td>
<td>38</td>
<td>14.00</td>
<td>AN</td>
<td>Outpatient</td>
<td>FBT/IND</td>
<td>IO</td>
<td>3-5/20</td>
<td>17.36</td>
<td>WAI</td>
<td>.35(.17)</td>
</tr>
<tr>
<td>Isserlin &amp; Couturier (2012)</td>
<td>13</td>
<td>14.00</td>
<td>AN</td>
<td>Outpatient</td>
<td>FBT/IND</td>
<td>IO</td>
<td>3/MDN=12</td>
<td>42.86</td>
<td>SOFTA</td>
<td>.55(.39)</td>
</tr>
<tr>
<td>Paulson Karlsson et al. (2013)</td>
<td>41</td>
<td>23.90</td>
<td>AN</td>
<td>MIX</td>
<td>Multi/MIX</td>
<td>PA</td>
<td>MO6/ MO18±19</td>
<td>38.00</td>
<td>TSS</td>
<td>.26(.15)</td>
</tr>
<tr>
<td>Prestano et al. (2008)</td>
<td>6</td>
<td>16.00</td>
<td>MUL</td>
<td>Outpatient</td>
<td>Other/GRP</td>
<td>PA</td>
<td>WK4/WK104</td>
<td>25.00</td>
<td>CAPAS</td>
<td>.07(.81)</td>
</tr>
<tr>
<td>Satir (2012)</td>
<td>6</td>
<td>26.90</td>
<td>AN</td>
<td>Outpatient</td>
<td>Multi/IND</td>
<td>PA</td>
<td>5/24</td>
<td>14.29</td>
<td>WAI</td>
<td>-.20(.50)</td>
</tr>
<tr>
<td>Simpson et al. (2005)</td>
<td>6</td>
<td>32.00</td>
<td>BN</td>
<td>Outpatient</td>
<td>CBT/IND</td>
<td>PA</td>
<td>4/17</td>
<td>0</td>
<td>ARM</td>
<td>-.38(.77)</td>
</tr>
<tr>
<td>Sly et al. (2013)</td>
<td>78</td>
<td>27.73</td>
<td>AN</td>
<td>Inpatient</td>
<td>Other/IND</td>
<td>PA</td>
<td>WK4/VAR</td>
<td>0</td>
<td>WAI</td>
<td>.23(.11)</td>
</tr>
<tr>
<td>Tasca &amp; Lampard (2012)</td>
<td>127</td>
<td>26.11</td>
<td>MUL</td>
<td>Outpatient</td>
<td>Multi/GRP</td>
<td>PA</td>
<td>WK4/WK12</td>
<td>28.00</td>
<td>CAPAS</td>
<td>.16(.08)</td>
</tr>
<tr>
<td>Thompson-Brenner (2013)</td>
<td>36</td>
<td>25.63</td>
<td>BN</td>
<td>Outpatient</td>
<td>CBT/IND</td>
<td>PA</td>
<td>3-5/20</td>
<td>24.00</td>
<td>WAI</td>
<td>-.52(.102)</td>
</tr>
<tr>
<td>Waller et al.(2012)</td>
<td>44</td>
<td>27.20</td>
<td>MUL</td>
<td>Outpatient</td>
<td>CBT/IND</td>
<td>PA</td>
<td>6/6</td>
<td>14.00</td>
<td>WAI</td>
<td>.18(.02)</td>
</tr>
<tr>
<td>Zaitsoff et al.(2008)(A)</td>
<td>33</td>
<td>11.25</td>
<td>BN</td>
<td>Outpatient</td>
<td>FBT/IND</td>
<td>PA</td>
<td>10/20</td>
<td>11.25</td>
<td>HRQ</td>
<td>-.39(.18)</td>
</tr>
<tr>
<td>Zaitsoff et al.(2008)(B)</td>
<td>29</td>
<td>11.25</td>
<td>BN</td>
<td>Outpatient</td>
<td>SPT/IND</td>
<td>PA</td>
<td>10/20</td>
<td>11.25</td>
<td>HRQ</td>
<td>.35(.19)</td>
</tr>
</tbody>
</table>
META-ANALYSIS OF THE RELATION BETWEEN ALLIANCE

Note. $\beta = .19$, confidence interval [$.11, .28$], $z = 4.38$, $p < .0001$; A = treatment arm A; B = treatment arm B; DX = sample diagnosis; AN = anorexia nervosa; BN = bulimia nervosa; MUL = multiple eating disorder diagnoses; MIX = multiple settings; CBT = cognitive behavioral therapy; IPT = interpersonal psychotherapy; AFT = adolescent-focused therapy; FBT = family-based therapy; SPT = supportive psychotherapy; IND = individual; GRP = group; PA = patient; IO = independent observer; VAR = varied; MDN = median; MO = months; WK = week; HAQ = Helping Alliance Questionnaire; WAI = Working Alliance Inventory; SOFTA = System for Observing Family Alliances; TSS = Treatment Satisfaction Scale; CAPAS = The California Psychotherapy Alliance Scales; ARM = Agnew Relationship Measure; HRQ = Helping Relationship Questionnaire; CI = confidence interval.

a The baseline measure of the outcome was not included in the regression analysis due to multicollinearity.
b The study effect size was based on total sample analyses.
c The study effect size was based on pairwise regression analyses.
META-ANALYSIS OF THE RELATION BETWEEN ALLIANCE

Table 2. Results of random-effects moderator analyses

<table>
<thead>
<tr>
<th>Moderator variable</th>
<th>Does early change in treatment outcome predict early/mid alliance?</th>
<th>Does early/mid alliance predict subsequent symptom change?</th>
<th>Does early/mid alliance predict subsequent symptom change above and beyond early symptoms change?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Q</td>
<td>df</td>
<td>P</td>
</tr>
<tr>
<td>Therapy type</td>
<td>1.56</td>
<td>3</td>
<td>.67</td>
</tr>
<tr>
<td>Mean age</td>
<td>2.77</td>
<td>1</td>
<td>.10</td>
</tr>
<tr>
<td>Eating disorder diagnosis</td>
<td>.07</td>
<td>2</td>
<td>.97</td>
</tr>
<tr>
<td>Alliance rater</td>
<td>.01</td>
<td>1</td>
<td>.93</td>
</tr>
<tr>
<td>Study drop-out rate</td>
<td>3.65</td>
<td>1</td>
<td>.06</td>
</tr>
</tbody>
</table>
META-ANALYSIS OF THE RELATION BETWEEN ALLIANCE

Table 3. Question 2: Does mid-to-end of treatment change in symptoms predict later alliance?

<table>
<thead>
<tr>
<th>Report</th>
<th>N</th>
<th>Mean age</th>
<th>DX</th>
<th>Therapy setting</th>
<th>Therapy type/mode</th>
<th>Alliance rater/session</th>
<th>Study drop-out (%)</th>
<th>Alliance rating measure</th>
<th>Effect size information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brown et al. (2013)</td>
<td>33</td>
<td>25.70</td>
<td>AN</td>
<td>Outpatient</td>
<td>CBT/IND</td>
<td>PA/EOT</td>
<td>32.31</td>
<td>WAI</td>
<td>.03(.21)$^b$</td>
</tr>
<tr>
<td>Fluckiger et al. (2011)(A)</td>
<td>29</td>
<td>45.93</td>
<td>BED</td>
<td>Outpatient</td>
<td>CBT/IND</td>
<td>PA/EOT</td>
<td>29.00</td>
<td>BPSRP</td>
<td>-.06(.20)$^a$</td>
</tr>
<tr>
<td>Fluckiger et al. (2011)(B)</td>
<td>26</td>
<td>45.93</td>
<td>BED</td>
<td>Outpatient</td>
<td>BWLT/IND</td>
<td>PA/EOT</td>
<td>29.00</td>
<td>BPSRP</td>
<td>.07(.21)$^a$</td>
</tr>
<tr>
<td>Isserlin &amp; Couturier (2012)</td>
<td>14</td>
<td>14.00</td>
<td>AN</td>
<td>Outpatient</td>
<td>BWLT/IND</td>
<td>IO/EOT</td>
<td>42.86</td>
<td>SOFTA</td>
<td>.26(.22)$^b$</td>
</tr>
<tr>
<td>Prestano et al. (2008)</td>
<td>6</td>
<td>16.00</td>
<td>MUL</td>
<td>Outpatient</td>
<td>Other/GRP</td>
<td>PA/EOT</td>
<td>25.16</td>
<td>CAPAS</td>
<td>.37(.49)$^a$</td>
</tr>
<tr>
<td>Simpson et al. (2005)</td>
<td>6</td>
<td>32.00</td>
<td>BN</td>
<td>Outpatient</td>
<td>CBT/IND</td>
<td>PA/EOT</td>
<td>0</td>
<td>ARM</td>
<td>.41(.60)$^a$</td>
</tr>
<tr>
<td>Tasca &amp; Lampard (2012)</td>
<td>65</td>
<td>26.11</td>
<td>MUL</td>
<td>Outpatient</td>
<td>Multi/GRP</td>
<td>PA/EOT</td>
<td>28.00</td>
<td>CAPAS</td>
<td>.17(.13)$^b$</td>
</tr>
<tr>
<td>Tasca et al. (2013)</td>
<td>49</td>
<td>44.30</td>
<td>BED</td>
<td>Outpatient</td>
<td>IPT/GRP</td>
<td>PA/EOT</td>
<td>18.00</td>
<td>CAPAS</td>
<td>.12(.19)$^b$</td>
</tr>
<tr>
<td>Zaitsoff et al.(2008)(A)</td>
<td>28</td>
<td>16.10</td>
<td>BN</td>
<td>Outpatient</td>
<td>FBT/IND</td>
<td>PA/EOT</td>
<td>11.25</td>
<td>HRQ</td>
<td>.02(.21)$^b$</td>
</tr>
<tr>
<td>Zaitsoff et al.(2008)(B)</td>
<td>24</td>
<td>16.10</td>
<td>BN</td>
<td>Outpatient</td>
<td>SPT/IND</td>
<td>PA/EOT</td>
<td>11.25</td>
<td>HRQ</td>
<td>-.26(.52)$^b$</td>
</tr>
</tbody>
</table>

Note. $\beta = .10, 95\% \text{CI } [-.04, .24], z = 1.46, p = .15$; A = treatment arm A; B = treatment arm B; DX = sample diagnosis; AN = anorexia nervosa; BN = bulimia nervosa; BED = binge eating disorder; MUL = multiple eating disorder diagnoses; CBT = cognitive behavioral therapy; IPT = interpersonal psychotherapy; BWLT = behavioral weight loss treatment; AFT = adolescent-focused therapy; FBT = family-based therapy; SPT = supportive psychotherapy; IND = individual; GRP = group; PA = patient; IO = independent observer; EOT = end of treatment; WAI=Working Alliance Inventory; BPSRP=Bern Post-Session Reports for Patients; SOFTA = System for Observing Family Therapy Alliances; CAPAS = The California Psychotherapy Alliance Scales; ARM = Agnew Relationship Measure; HRQ = Helping Relationship Questionnaire; CI = confidence interval.

$^a$The study effect size was based on total sample analyses.

$^b$The study effect size was based on pairwise regression analyses.
META-ANALYSIS OF THE RELATION BETWEEN ALLIANCE

Table 4. Question 3: Does change in symptoms across treatment predict later alliance?

<table>
<thead>
<tr>
<th>Report</th>
<th>N</th>
<th>Mean age</th>
<th>DX</th>
<th>Therapy setting</th>
<th>Therapy type/mode</th>
<th>Alliance rater/session</th>
<th>Study drop-out (%)</th>
<th>Alliance rating measure</th>
<th>β(SE)</th>
<th>95% CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brown et al. (2013)</td>
<td>31</td>
<td>25.70</td>
<td>AN</td>
<td>Outpatient</td>
<td>CBT/IND</td>
<td>PA/EOT</td>
<td>32.31</td>
<td>WAI</td>
<td>.11(.21)c</td>
<td>-.29, .51</td>
<td>.58</td>
</tr>
<tr>
<td>Fluckiger et al. (2011)(A)</td>
<td>29</td>
<td>45.93</td>
<td>BED</td>
<td>Outpatient</td>
<td>CBT/IND</td>
<td>PA/EOT</td>
<td>29.00</td>
<td>BPSRP</td>
<td>.17(.20)b</td>
<td>-.21, .56</td>
<td>.37</td>
</tr>
<tr>
<td>Fluckiger et al. (2011)(B)</td>
<td>26</td>
<td>45.93</td>
<td>BED</td>
<td>Outpatient</td>
<td>BWLT/IND</td>
<td>PA/EOT</td>
<td>29.00</td>
<td>BPSRP</td>
<td>.17(.21)b</td>
<td>-.23, .58</td>
<td>.41</td>
</tr>
<tr>
<td>Isserlin &amp; Couturier (2012)</td>
<td>14</td>
<td>14.00</td>
<td>AN</td>
<td>Outpatient</td>
<td>FBT/IND</td>
<td>IO/EOT</td>
<td>42.86</td>
<td>SOFTA</td>
<td>.38(.26)c</td>
<td>-.12, .89</td>
<td>.14</td>
</tr>
<tr>
<td>Mander et al. (2013)</td>
<td>39</td>
<td>27.70</td>
<td>AN</td>
<td>Inpatient</td>
<td>Multi/MIX</td>
<td>PA/EOT</td>
<td>28.00</td>
<td>SACiP</td>
<td>.21(.17)</td>
<td>-.12, .54</td>
<td>.21</td>
</tr>
<tr>
<td>Mitchell et al. (2008)(A)</td>
<td>35</td>
<td>29.60</td>
<td>BN</td>
<td>Outpatient</td>
<td>CBT/IND</td>
<td>PA/EOT</td>
<td>37.50</td>
<td>WAI</td>
<td>.57(.29)c</td>
<td>.01, 1.13</td>
<td>.05</td>
</tr>
<tr>
<td>Mitchell et al. (2008)(B)</td>
<td>36</td>
<td>28.40</td>
<td>BN</td>
<td>Outpatient</td>
<td>CBT/IND</td>
<td>PA/EOT</td>
<td>37.50</td>
<td>WAI</td>
<td>.09(.45)ac</td>
<td>-.80, .98</td>
<td>.85</td>
</tr>
<tr>
<td>Prestano et al. (2008)</td>
<td>6</td>
<td>16.00</td>
<td>MUL</td>
<td>Outpatient</td>
<td>Other/GRP</td>
<td>PA/EOT</td>
<td>25.00</td>
<td>CAPAS</td>
<td>.42(.66)ab</td>
<td>-.87, 1.71</td>
<td>.52</td>
</tr>
<tr>
<td>Simpson et al. (2005)</td>
<td>6</td>
<td>32.00</td>
<td>BN</td>
<td>Outpatient</td>
<td>CBT/IND</td>
<td>PA/EOT</td>
<td>0</td>
<td>ARM</td>
<td>.06(.55)bc</td>
<td>-1.01, 1.13</td>
<td>.91</td>
</tr>
<tr>
<td>Stiles-Shields et al. (2013)(A)</td>
<td>24</td>
<td>33.40</td>
<td>AN</td>
<td>Outpatient</td>
<td>CBT/IND</td>
<td>PA/EOT</td>
<td>22.58</td>
<td>HAQ</td>
<td>.66(.19)c</td>
<td>.29, 1.04</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Stiles-Shields et al. (2013)(B)</td>
<td>28</td>
<td>33.40</td>
<td>AN</td>
<td>Outpatient</td>
<td>SSCT/IND</td>
<td>PA/EOT</td>
<td>12.50</td>
<td>HAQ</td>
<td>.33(.20)c</td>
<td>-.06, .72</td>
<td>.10</td>
</tr>
<tr>
<td>Tasca &amp; Lampard (2012)</td>
<td>65</td>
<td>26.11</td>
<td>MUL</td>
<td>Outpatient</td>
<td>Multi/GRP</td>
<td>PA/EOT</td>
<td>28.00</td>
<td>CAPAS</td>
<td>.20(.13)c</td>
<td>-.06, .46</td>
<td>.13</td>
</tr>
<tr>
<td>Tasca et al.(2007)(A)</td>
<td>38</td>
<td>43.86</td>
<td>BED</td>
<td>Outpatient</td>
<td>CBT/GRP</td>
<td>PA/EOT</td>
<td>22.73</td>
<td>CAPAS</td>
<td>.08(.20)c</td>
<td>-.30, .47</td>
<td>.68</td>
</tr>
<tr>
<td>Tasca et al.(2007)(B)</td>
<td>52</td>
<td>43.86</td>
<td>BED</td>
<td>Outpatient</td>
<td>IPT/GRP</td>
<td>PA/EOT</td>
<td>22.73</td>
<td>CAPAS</td>
<td>-.20(.15)c</td>
<td>-.50, .10</td>
<td>.19</td>
</tr>
<tr>
<td>Tasca et al. (2013)</td>
<td>72</td>
<td>44.30</td>
<td>BED</td>
<td>Outpatient</td>
<td>IPT/GRP</td>
<td>PA/WK16</td>
<td>18.00</td>
<td>CAPAS</td>
<td>.12(.13)c</td>
<td>-.14, .39</td>
<td>.35</td>
</tr>
<tr>
<td>Thompson-Brenner et al. (2013)</td>
<td>72</td>
<td>25.63</td>
<td>BN</td>
<td>Outpatient</td>
<td>CBT/IND</td>
<td>PA/14-EOT</td>
<td>24.00</td>
<td>WAI</td>
<td>.42(.24)c</td>
<td>-.05, .89</td>
<td>.08</td>
</tr>
</tbody>
</table>

Note. β = .17, 95% CI [.06, .29], z = 2.96, p = .003; A = treatment arm A; B = treatment arm B; DX = sample diagnosis; AN = anorexia nervosa; BN = bulimia nervosa; BED = binge eating disorder; MUL = multiple eating disorder diagnoses; CBT = cognitive behavioral therapy; IPT = interpersonal psychotherapy; BWLT = behavioral weight loss treatment; AFT = adolescent-focused therapy; FBT = family-based therapy; SPT = supportive psychotherapy; SSCT = specialist supportive clinical management; IND = individual; GRP = group; PA = patient; IO = independent observer; WK = week; EOT = end of treatment; WAI = Working Alliance Inventory; BPSRP = Bern Post-Session Reports for Patients; SOFTA = System for Observing Family Therapy Alliances; SACiP = Scale for the Multiperspective Assessment of General Change Mechanisms in Psychotherapy; CAPAS = The California Psychotherapy Alliance Scales; ARM = Agnew Relationship Measure; HAQ = Helping Alliance Questionnaire; HRQ = Helping Relationship Questionnaire; CI = confidence interval.

The baseline measure of the outcome was not included in the regression analysis due to multicolinearity.
META-ANALYSIS OF THE RELATION BETWEEN ALLIANCE

\textsuperscript{b} The study effect size was based on total sample analyses.
\textsuperscript{c} The study effect size was based on pairwise regression analyses.
## META-ANALYSIS OF THE RELATION BETWEEN ALLIANCE

Table 5. Question 4a: Does early/mid alliance predict subsequent change in symptoms?

<table>
<thead>
<tr>
<th>Report</th>
<th>N</th>
<th>Mean age</th>
<th>DX</th>
<th>Therapy setting</th>
<th>Therapy type/mode</th>
<th>Alliance rater</th>
<th>Session/ of Total</th>
<th>Study dropout (%)</th>
<th>Alliance rating measure</th>
<th>Effect size information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bourion-Bedes et al. (2013)(A)</td>
<td>66</td>
<td>15.30</td>
<td>AN</td>
<td>Inpatient</td>
<td>Multi/IND</td>
<td>PA</td>
<td>3/VAR</td>
<td>0</td>
<td>HAQ</td>
<td>.27(.12)&lt;sup&gt;a&lt;/sup&gt; .04, .51 .02</td>
</tr>
<tr>
<td>Bourion-Bedes et al. (2013)(B)</td>
<td>42</td>
<td>15.30</td>
<td>AN</td>
<td>Outpatient</td>
<td>Multi/IND</td>
<td>PA</td>
<td>3/VAR</td>
<td>0</td>
<td>HAQ</td>
<td>.35(.16)&lt;sup&gt;a&lt;/sup&gt; .04, .66 .03</td>
</tr>
<tr>
<td>Brown et al. (2013)</td>
<td>33</td>
<td>25.70</td>
<td>AN</td>
<td>Outpatient</td>
<td>CBT/IND</td>
<td>PA</td>
<td>6/30-40</td>
<td>32.31</td>
<td>WAI</td>
<td>-.25(.15)&lt;sup&gt;b&lt;/sup&gt; -.54, .05 .10</td>
</tr>
<tr>
<td>Constantino et al. (2005)(A)</td>
<td>72</td>
<td>28.10</td>
<td>BN</td>
<td>Outpatient</td>
<td>CBT/IND</td>
<td>PA</td>
<td>12/19</td>
<td>25.91</td>
<td>HAQ</td>
<td>.11(.11)&lt;sup&gt;b&lt;/sup&gt; -.10, .32 .31</td>
</tr>
<tr>
<td>Constantino et al. (2005)(B)</td>
<td>76</td>
<td>28.10</td>
<td>BN</td>
<td>Outpatient</td>
<td>IPT/IND</td>
<td>PA</td>
<td>12/19</td>
<td>25.91</td>
<td>HAQ</td>
<td>-.05(.08)&lt;sup&gt;b&lt;/sup&gt; -.21, .12 .56</td>
</tr>
<tr>
<td>Fluckiger et al. (2011)(A)</td>
<td>29</td>
<td>45.93</td>
<td>BED</td>
<td>Outpatient</td>
<td>CBT/IND</td>
<td>PA</td>
<td>6/22</td>
<td>29.00</td>
<td>BPSRP</td>
<td>.13(.16)&lt;sup&gt;a&lt;/sup&gt; -.25, .51 .51</td>
</tr>
<tr>
<td>Fluckiger et al. (2011)(B)</td>
<td>26</td>
<td>45.93</td>
<td>BED</td>
<td>Outpatient</td>
<td>BWLT/IND</td>
<td>PA</td>
<td>6/22</td>
<td>29.00</td>
<td>BPSRP</td>
<td>-.03(.22)&lt;sup&gt;a&lt;/sup&gt; -.45, .40 .90</td>
</tr>
<tr>
<td>Forsberg et al. (2013)(A)</td>
<td>40</td>
<td>14.80</td>
<td>AN</td>
<td>Outpatient</td>
<td>AFT/IND</td>
<td>IO</td>
<td>3-5/20</td>
<td>17.36</td>
<td>WAI</td>
<td>.13(.16)&lt;sup&gt;a&lt;/sup&gt; -.18, .44 .41</td>
</tr>
<tr>
<td>Forsberg et al. (2013)(B)</td>
<td>38</td>
<td>14.00</td>
<td>AN</td>
<td>Outpatient</td>
<td>FBT/IND</td>
<td>IO</td>
<td>3-5/20</td>
<td>17.36</td>
<td>WAI</td>
<td>.23(.16)&lt;sup&gt;a&lt;/sup&gt; -.09, .55 .16</td>
</tr>
<tr>
<td>Isserlin &amp; Couturier (2012)</td>
<td>13</td>
<td>14.00</td>
<td>AN</td>
<td>Outpatient</td>
<td>FBT/IND</td>
<td>IO</td>
<td>3/MDN=12</td>
<td>42.86</td>
<td>SOFTA</td>
<td>.25(.33)&lt;sup&gt;b&lt;/sup&gt; -.40, .90 .46</td>
</tr>
<tr>
<td>Paulson Karlsson et al. (2013)</td>
<td>47</td>
<td>23.90</td>
<td>MIX</td>
<td>Multi/MIX</td>
<td>Multi/MIX</td>
<td>PA</td>
<td>38.00</td>
<td>TSS</td>
<td>.21(.15)&lt;sup&gt;b&lt;/sup&gt; -.09, .50 .18</td>
<td></td>
</tr>
<tr>
<td>Mander et al. (2013)</td>
<td>39</td>
<td>27.70</td>
<td>AN</td>
<td>Inpatient</td>
<td>Multi/MIX</td>
<td>PA</td>
<td>28.00</td>
<td>SACiP</td>
<td>.37(.17)&lt;sup&gt;a&lt;/sup&gt; .04, .70 .03</td>
<td></td>
</tr>
<tr>
<td>Prestano et al. (2008)</td>
<td>6</td>
<td>16.00</td>
<td>MUL</td>
<td>Outpatient</td>
<td>Other/GRP</td>
<td>PA</td>
<td>25.00</td>
<td>CAPAS</td>
<td>.59(.77)&lt;sup&gt;a&lt;/sup&gt; -.93, 2.01 .45</td>
<td></td>
</tr>
<tr>
<td>Simpson et al. (2005)</td>
<td>6</td>
<td>32.00</td>
<td>BN</td>
<td>Outpatient</td>
<td>CBT/IND</td>
<td>PA</td>
<td>0</td>
<td>ARM</td>
<td>-.56(.60)&lt;sup&gt;a&lt;/sup&gt; -.174, .62 .35</td>
<td></td>
</tr>
<tr>
<td>Sly et al. (2013)</td>
<td>78</td>
<td>27.73</td>
<td>AN</td>
<td>Inpatient</td>
<td>Other/IND</td>
<td>PA</td>
<td>0</td>
<td>WAI</td>
<td>-.10(.13)&lt;sup&gt;b&lt;/sup&gt; -.35, .15 .44</td>
<td></td>
</tr>
<tr>
<td>Tasca &amp; Lampard (2012)</td>
<td>89</td>
<td>26.11</td>
<td>MUL</td>
<td>Outpatient</td>
<td>Multi/GRP</td>
<td>PA</td>
<td>28.00</td>
<td>CAPAS</td>
<td>.13(.09)&lt;sup&gt;b&lt;/sup&gt; -.04, .30 .14</td>
<td></td>
</tr>
<tr>
<td>Tasca et al. (2013)</td>
<td>50</td>
<td>44.30</td>
<td>BED</td>
<td>Outpatient</td>
<td>IPT/GRP</td>
<td>PA</td>
<td>18.00</td>
<td>CAPAS</td>
<td>.26(.11)&lt;sup&gt;b&lt;/sup&gt; .05, .48 .02</td>
<td></td>
</tr>
<tr>
<td>Zaitsoff et al.(2008)(A)</td>
<td>28</td>
<td>16.10</td>
<td>BN</td>
<td>Outpatient</td>
<td>FBT/IND</td>
<td>PA</td>
<td>10/20</td>
<td>HRQ</td>
<td>.45(.20)&lt;sup&gt;b&lt;/sup&gt; .06, .84 .03</td>
<td></td>
</tr>
<tr>
<td>Zaitsoff et al.(2008)(B)</td>
<td>26</td>
<td>16.10</td>
<td>BN</td>
<td>Outpatient</td>
<td>SPT/IND</td>
<td>PA</td>
<td>10/20</td>
<td>HRQ</td>
<td>.14(.20)&lt;sup&gt;b&lt;/sup&gt; -.26, .54 .50</td>
<td></td>
</tr>
</tbody>
</table>
Note.  β = .13, 95% CI [.05, .22], z = 3.10, p = .002; A = treatment arm A; B = treatment arm B; DX = sample diagnosis; AN = anorexia nervosa; BN = bulimia nervosa; BED = binge eating disorder; MUL = multiple eating disorder diagnoses; CBT = cognitive behavioral therapy; IPT = interpersonal psychotherapy; BWLT = behavioral weight loss treatment; AFT = adolescent-focused therapy; FBT = family-based therapy; SPT = supportive psychotherapy; IND = individual; GRP = group; PA = patient; IO = independent observer; VAR = varied; MDN = median; MO = month; DAYS = days; WK = week; HAQ = Helping Alliance Questionnaire; WAI=Working Alliance Inventory; BPSRP = Bern Post-Session Reports for Patients; SOFTA = System for Observing Family Therapy Alliances; TSS = Treatment Satisfaction Scale; SACiP = Scale for the Multiperspective Assessment of General Change Mechanisms in Psychotherapy; CAPAS = The California Psychotherapy Alliance Scales; ARM = Agnew Relationship Measure; HRQ = Helping Relationship Questionnaire; CI = confidence interval.

The study effect size was based on total sample analyses.

The study effect size was based on pairwise regression analyses.
<table>
<thead>
<tr>
<th>Report</th>
<th>N</th>
<th>Mean age</th>
<th>DX</th>
<th>Therapy setting</th>
<th>Therapy type/mode</th>
<th>Alliance rater</th>
<th>Session of Total</th>
<th>Study dropout (%)</th>
<th>Alliance rating measure</th>
<th>Effect size information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bourion-Bedes et al. (2013)(A)</td>
<td>66</td>
<td>15.30</td>
<td>AN</td>
<td>Inpatient</td>
<td>Multi/IND</td>
<td>PA</td>
<td>3/VAR</td>
<td>0</td>
<td>HAQ</td>
<td>.31(.11)</td>
</tr>
<tr>
<td>Bourion-Bedes et al. (2013)(B)</td>
<td>42</td>
<td>15.30</td>
<td>AN</td>
<td>Outpatient</td>
<td>Multi/IND</td>
<td>PA</td>
<td>3/VAR</td>
<td>0</td>
<td>HAQ</td>
<td>.27(.14)</td>
</tr>
<tr>
<td>Brown et al. (2013)</td>
<td>33</td>
<td>25.70</td>
<td>AN</td>
<td>Outpatient</td>
<td>CBT/IND</td>
<td>PA</td>
<td>6/30-40</td>
<td>32.31</td>
<td>WAI</td>
<td>-.14(.19)</td>
</tr>
<tr>
<td>Constantino et al. (2005)(A)</td>
<td>72</td>
<td>28.10</td>
<td>BN</td>
<td>Outpatient</td>
<td>CBT/IND</td>
<td>PA</td>
<td>12/19</td>
<td>25.91</td>
<td>HAQ</td>
<td>-.15(.12)</td>
</tr>
<tr>
<td>Constantino et al. (2005)(B)</td>
<td>76</td>
<td>28.10</td>
<td>BN</td>
<td>Outpatient</td>
<td>IPT/IND</td>
<td>PA</td>
<td>12/19</td>
<td>25.91</td>
<td>HAQ</td>
<td>-.20(.12)</td>
</tr>
<tr>
<td>Forsberg et al. (2013)(A)</td>
<td>40</td>
<td>14.80</td>
<td>AN</td>
<td>Outpatient</td>
<td>AFT/IND</td>
<td>IO</td>
<td>3-5/32</td>
<td>17.36</td>
<td>WAI</td>
<td>.17(.16)</td>
</tr>
<tr>
<td>Forsberg et al. (2013)(B)</td>
<td>38</td>
<td>14.00</td>
<td>AN</td>
<td>Outpatient</td>
<td>FBT/IND</td>
<td>IO</td>
<td>3-5/20</td>
<td>17.36</td>
<td>WAI</td>
<td>.25(.18)</td>
</tr>
<tr>
<td>Isserlin &amp; Couturier (2012)</td>
<td>13</td>
<td>14.00</td>
<td>AN</td>
<td>Outpatient</td>
<td>FBT/IND</td>
<td>IO</td>
<td>M3/M6=12</td>
<td>42.86</td>
<td>SOFTA</td>
<td>.30(.34)</td>
</tr>
<tr>
<td>Paulson Karlsson et al. (2013)</td>
<td>47</td>
<td>23.90</td>
<td>AN</td>
<td>MIX</td>
<td>Multi/MIX</td>
<td>PA</td>
<td></td>
<td></td>
<td>TSS</td>
<td>.19(.15)</td>
</tr>
<tr>
<td>Prestano et al. (2008)</td>
<td>6</td>
<td>16.00</td>
<td>MUL</td>
<td>Outpatient</td>
<td>Other/GRP</td>
<td>PA</td>
<td>WK4/WK104</td>
<td>25.00</td>
<td>CAPAS</td>
<td>-.07(.77)</td>
</tr>
<tr>
<td>Simpson et al. (2005)</td>
<td>6</td>
<td>32.00</td>
<td>BN</td>
<td>Outpatient</td>
<td>CBT/IND</td>
<td>PA</td>
<td>4/17</td>
<td>0</td>
<td>ARM</td>
<td>-.35(.42)</td>
</tr>
<tr>
<td>Sly et al. (2013)</td>
<td>78</td>
<td>27.73</td>
<td>AN</td>
<td>Inpatient</td>
<td>Other/IND</td>
<td>PA</td>
<td>4/VAR</td>
<td>0</td>
<td>WAI</td>
<td>-.07(.12)</td>
</tr>
<tr>
<td>Tasca &amp; Lampard (2012)</td>
<td>89</td>
<td>26.11</td>
<td>MUL</td>
<td>Outpatient</td>
<td>Multi/GRP</td>
<td>PA</td>
<td>WK4/WK12</td>
<td>28.00</td>
<td>CAPAS</td>
<td>.07(.11)</td>
</tr>
<tr>
<td>Zaitsoff et al.(2008)(A)</td>
<td>28</td>
<td>16.10</td>
<td>BN</td>
<td>Outpatient</td>
<td>FBT/IND</td>
<td>PA</td>
<td>10/20</td>
<td>11.25</td>
<td>HRQ</td>
<td>-.03(.21)</td>
</tr>
<tr>
<td>Zaitsoff et al.(2008)(B)</td>
<td>26</td>
<td>16.10</td>
<td>BN</td>
<td>Outpatient</td>
<td>SPT/IND</td>
<td>PA</td>
<td>10/20</td>
<td>11.25</td>
<td>HRQ</td>
<td>.28(.20)</td>
</tr>
</tbody>
</table>

Note. β = .07, 95% CI [-.04, .17], z = 1.26, p = .21; A = treatment arm A; B = treatment arm B; DX = sample diagnosis; AN = anorexia nervosa; BN = bulimia nervosa; BED = binge eating disorder; MUL = multiple eating disorder diagnoses; CBT = cognitive behavioral therapy; IPT = interpersonal psychotherapy; BWLT = behavioral weight loss treatment; AFT = adolescent-focused therapy; FBT = family-based therapy; SPT = supportive psychotherapy; IND = individual; GRP = group; PA = patient; IO = independent observer; VAR = varied; MDN = median; MO = month; WK = week; HAQ = Helping Alliance Questionnaire; WAI=Working Alliance Inventory; HAQ = Helping Alliance Questionnaire; SOFTA = System for Observing Family Therapy Alliances; TSS = Treatment Satisfaction Scale; CAPAS = The California Psychotherapy Alliance Scales; ARM = Agnew Relationship Measure; HRQ = Helping Relationship Questionnaire; CI = confidence interval.

aThe study effect size was based on total sample analyses.

bThe study effect size was based on pairwise regression analyses.
META-ANALYSIS OF THE RELATION BETWEEN ALLIANCE